- Home
- PULM vs LVTX Comparison
PULM vs LVTX Comparison
Compare PULM & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- LVTX
- Stock Information
- Founded
- PULM 2003
- LVTX 2016
- Country
- PULM United States
- LVTX Netherlands
- Employees
- PULM N/A
- LVTX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- LVTX Health Care
- Exchange
- PULM Nasdaq
- LVTX Nasdaq
- Market Cap
- PULM 33.2M
- LVTX 33.9M
- IPO Year
- PULM N/A
- LVTX 2021
- Fundamental
- Price
- PULM $7.43
- LVTX $1.31
- Analyst Decision
- PULM
- LVTX Hold
- Analyst Count
- PULM 0
- LVTX 3
- Target Price
- PULM N/A
- LVTX $1.75
- AVG Volume (30 Days)
- PULM 34.2K
- LVTX 38.7K
- Earning Date
- PULM 08-12-2025
- LVTX 08-19-2025
- Dividend Yield
- PULM N/A
- LVTX N/A
- EPS Growth
- PULM N/A
- LVTX N/A
- EPS
- PULM N/A
- LVTX N/A
- Revenue
- PULM $1,921,000.00
- LVTX $4,990,000.00
- Revenue This Year
- PULM N/A
- LVTX N/A
- Revenue Next Year
- PULM $134.88
- LVTX N/A
- P/E Ratio
- PULM N/A
- LVTX N/A
- Revenue Growth
- PULM N/A
- LVTX N/A
- 52 Week Low
- PULM $1.78
- LVTX $0.85
- 52 Week High
- PULM $10.40
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- PULM 49.28
- LVTX 51.02
- Support Level
- PULM $8.49
- LVTX $1.28
- Resistance Level
- PULM $8.75
- LVTX $1.40
- Average True Range (ATR)
- PULM 0.42
- LVTX 0.05
- MACD
- PULM -0.14
- LVTX -0.00
- Stochastic Oscillator
- PULM 0.11
- LVTX 52.63
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.